Ontology highlight
ABSTRACT:
SUBMITTER: Iwanami A
PROVIDER: S-EPMC3600508 | biostudies-other | 2013 Mar
REPOSITORIES: biostudies-other
Proceedings of the National Academy of Sciences of the United States of America 20130225 11
Despite their nearly universal activation of mammalian target of rapamycin (mTOR) signaling, glioblastomas (GBMs) are strikingly resistant to mTOR-targeted therapy. We analyzed GBM cell lines, patient-derived tumor cell cultures, and clinical samples from patients in phase 1 clinical trials, and find that the promyelocytic leukemia (PML) gene mediates resistance to mTOR-targeted therapies. Direct mTOR inhibitors and EGF receptor (EGFR) inhibitors that block downstream mTOR signaling promote nucl ...[more]